Treatment of metastasis
First Claim
Patent Images
1. A method for preventing metastatic disease in a human or animal suffering from a tumor without treating the primary tumor, the method comprising:
- administering a forskolin compound to said human or animal in amount effective to inhibit metastatic tumor cell-platelet interactions, the compound having the formula;
##STR4## where R1 is hydrogen or a hydroxy or lower alkoxy, sulfonate or carbonate group;
where R2 is a hydroxy, carbonate, acetyl, or acetoxy or lower alkanoyl group;
where R3 is a hydroxy, carbonate, acetyl or acetoxy or lower alkanoyl or tosyl group;
where R4 is hydrogen or a hydroxy or lower alkoxy, sulfonate or carbonate group;
where R5 is either double-bonded oxygen or separately bound hydrogen and hydroxy groups; and
where R6 is a lower alkene or oxygen.
0 Assignments
0 Petitions
Accused Products
Abstract
A method for reducing the incidence of metastasis in tumor victims without treating the primary tumor per se resides in the administration of forskolin or its analogs which are potent inhibitors of platelet aggregation. Forskolin compounds are generally defined as labdane diterpenoids having the general formula: ##STR1## These compounds may be administered alone or in combination with other inhibitors of platelet aggregation.
33 Citations
10 Claims
-
1. A method for preventing metastatic disease in a human or animal suffering from a tumor without treating the primary tumor, the method comprising:
- administering a forskolin compound to said human or animal in amount effective to inhibit metastatic tumor cell-platelet interactions, the compound having the formula;
##STR4## where R1 is hydrogen or a hydroxy or lower alkoxy, sulfonate or carbonate group;where R2 is a hydroxy, carbonate, acetyl, or acetoxy or lower alkanoyl group; where R3 is a hydroxy, carbonate, acetyl or acetoxy or lower alkanoyl or tosyl group; where R4 is hydrogen or a hydroxy or lower alkoxy, sulfonate or carbonate group; where R5 is either double-bonded oxygen or separately bound hydrogen and hydroxy groups; and where R6 is a lower alkene or oxygen. - View Dependent Claims (2, 3, 4, 5)
- administering a forskolin compound to said human or animal in amount effective to inhibit metastatic tumor cell-platelet interactions, the compound having the formula;
-
6. A pharmaceutical composition for preventing metastatic disease in a human or animal suffering from a tumor without treating the primary tumor, the composition comprising an effective amount of forskolin compound having the formula ##STR6## where R1 is hydrogen or a hydroxy or lower alkoxy, sulfonate or carbonate group;
-
where R2 is a hydroxy, carbonate, acetyl, or acetoxy or lower alkanoyl group; where R3 is a hydroxy, carbonate, acetyl or acetoxy or lower alkanoyl or tosyl group; where R4 is hydrogen or a hydroxy or lower alkoxy, carbonate or carbonate group; where R5 is either double-bonded oxygen or separately bound hydrogen and hydroxy groups; and where R6 is a lower alkene or oxygen, and a nucleoside transport inhibitor selected from the group consisting of p-nitrobenzylthionosine, dilazep, dipyridamole, oxagrelate and papervine in an amount effective to retard adenosine uptake by red blood cells. - View Dependent Claims (7)
-
-
8. A pharmaceutical composition for preventing metastatic disease in a human or animal suffering from a tumor without treating the primary tumor the composition comprising an effective amount of a forskolin compound having the formula:
- ##STR8## where R1 is hydrogen or a hydroxy or lower alkoxy, sulfonate or carbonate group;
where R2 is a hydroxy, carbonate, acetyl, or acetoxy or lower alkanoyl group; where R3 is a hydroxy, carbonate, acetyl or acetoxy or lower alkanoyl or tosyl group; where R4 is hydrogen or a hydroxy or lower alkoxy, sulfonate or carbonate group; where R5 is either double-bonded oxygen or separately bound hydrogen and hydroxy groups; and where R6 is a lower alkene or oxygen, and a cAMP-blocking agent selected from the group consisting of theophylline, dipyridamole, oxagrelate and papaverine in an amount effective to block the action of cAMP phosphodiesterase in converting cAMP to AMP. - View Dependent Claims (9, 10)
- ##STR8## where R1 is hydrogen or a hydroxy or lower alkoxy, sulfonate or carbonate group;
Specification